UNSPSC 51373326: Aspirin/carisoprodol/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373326 Aspirin/carisoprodol/codeine is a Commodity code that captures pharmaceutical supply procurement by state and local health agencies, though recent solicitations tagged under this code show significant scope mismatch — the actual work being solicited ranges from naloxone and drug deactivation systems to generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, to exploratory direct-to-manufacturer prescription programs. State health agencies and county health departments are the primary issuing bodies, supplemented by regional cooperative purchasing alliances that aggregate demand across multiple states and local jurisdictions. The work itself spans routine inventory replenishment of generic and OTC medications through established wholesale distribution networks, procurement of emergency-response pharmaceuticals such as naloxone for community health initiatives, and strategic program design for alternative pharmacy benefit arrangements outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity reflects a mix of geographies and procurement approaches. Seminole County, Florida, issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota, Oregon, and other jurisdictions, with a March 26, 2026 response deadline and awards effective July 1, 2026; the RFP requires vendors to supply through three authorized wholesalers and emphasizes price competitiveness (75 percent of evaluation weight) and cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for bypassing traditional pharmacy benefit manager and wholesaler arrangements. No explicit set-asides or disadvantaged-enterprise designations appear in the available solicitation materials.